ArticlePDF Available

Abstract and Figures

Two sensitive and selective polyvinyl chloride (PVC) matrix membrane sensors were developed and investigated for determination of the cationic drug Quetiapine Fumarate (QTF) in pure form, in plasma and in presence of its two related compounds namely Quetiapine N-oxide and Des-ethanol Quetiapine. The two sensors (Ι and ΙΙ) were developed using sodium tetraphenyl borate as a cation exchanger with dioctyl phthalate (DOP) as a plasticizer. Selective molecular recognition component, β-cyclodextrin (β-CD), was used as ionophore to improve the selectivity of sensor II. The proposed sensors had a linear dynamic range of 1×10-6-1×10-2 mol L-1 for sensor Ι and 1×10-7-1×10-2 mol L-1 for sensor ΙΙ with Nernstian slopes of 27.50±0.45 and 39.85±0.3 mV/decade for sensors I and II, respectively over the pH ranges of 2.5-7. The method was validated according to ICH guidelines. Statistical comparison between the results from the proposed method and the results from the reference HPLC method showed no significant difference regarding the accuracy and precision.
Content may be subject to copyright.
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63
Full Paper
Novel Membrane Sensors for the Determination of
Quetiapine Fumarate in Plasma and in Presence of its
Related Compounds
Marianne Nebsen,1,2 Christine M. El-Maraghy,3,* Hesham Salem4 and Sawsan M. Amer1
1Analytical Chemistry department, Faculty of Pharmacy, Cairo University, Kasr-El Aini Street,
11562Cairo, Egypt
2Pharmaceutical Analytical Chemistry department, Faculty of Pharmacy & Drug Technology,
Heliopolis University, 3 Cairo Belbeis desert road, 2834El- Horria, Cairo, Egypt
3Analytical Chemistry department, Faculty of Pharmacy, October University for Modern
Sciences and Arts(MSA), 11787 6th October city, Egypt
4Pharmaceutical Analytical Chemistry department, Faculty of Pharmacy, Deraya University,
Minia, Egypt
* Corresponding Author, Tel.: +201223553561
E-Mail: Christine_elmaraghy@hotmail.com
Received: 14 October 2015/Accepted: 26 January 2016 /Published online: 15 February 2016
Abstract- Two sensitive and selective polyvinyl chloride (PVC) matrix membrane sensors
were developed and investigated for determination of the cationic drug Quetiapine Fumarate
(QTF) in pure form, in plasma and in presence of its two related compounds namely Quetiapine
N-oxide and Des-ethanol Quetiapine. The two sensors (Ι and ΙΙ) were developed using sodium
tetraphenyl borate as a cation exchanger with dioctyl phthalate (DOP) as a plasticizer. Selective
molecular recognition component, β-cyclodextrin (β-CD), was used as ionophore to improve
the selectivity of sensor II. The proposed sensors had a linear dynamic range of 1×10-6-1×10-2
mol L-1 for sensor Ι and 1×10-7-1×10-2 mol L-1 for sensor ΙΙ with Nernstian slopes of 27.50±0.45
and 39.85±0.3 mV/decade for sensors I and II, respectively over the pH ranges of 2.5-7. The
method was validated according to ICH guidelines. Statistical comparison between the results
from the proposed method and the results from the reference HPLC method showed no
significant difference regarding the accuracy and precision.
Keywords- Quetiapine Fumarate, Ion selective electrode, Membrane sensors, Cationic
exchanger, Related compounds, Plasma
Analytical &
Bioanalytical
Electrochemistry
2016 by CEE
www.abechem.com
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 52
1. INTRODUCTION
Development of analytical methods for the determination of pharmaceuticals in the
presence of related compounds without previous chemical separation is always a matter of
interest. Our scientific motivation is developing a simple, accurate, low - cost, reproducible
and rapid membrane sensor for the determination of QTF drug in pure form, in dosage form,
plasma and in presence of its two related compounds; Des-ethanol Quetiapine (DQ) and
Quetiapine N-oxide (QO) without the need for pretreatment or prior separation.
Quetiapine (QTF) (Fig. 1), is a dibenzothiazepine derivative and classified as an atypical
antipsychotic with demonstrated efficacy in acute schizophrenia [1]. Several methods have
been reported for the determination of QTF in bulk powder, pharmaceutical preparations and
biological samples. These included UV-Visible spectrophotometric methods [2-4], HPLC
methods [5-10], HPTLC-densitometric methods [11,12], Capillary electrophoresis [13,14],
voltammetry [15,16] and potentiometry [17].
From the literatures, QTF was found to be most susceptible to oxidative degradation and
shows no or minimal degradation to acid, base, thermal and photo degradation [18,19]. During
stability studies, Quetiapine N-oxide (oxidation product) at level 0.1% was detected by ion-
pair reversed-phase high performance liquid chromatography (HPLC) [20]. In the process of
synthesis of QTF according to the Scheme (Warawa and Migler 1989); seven impurities were
identified ranging from 0.05–0.15% by high performance liquid chromatography (HPLC).
Based on the spectral data, one of them is des-ethanol quetiapine [21].
Most of the reported methods for determination of QTF involve complicated procedures,
sample pretreatment, long analysis times, expensive instruments and extraction operations that
are open to various interferences, and they are inapplicable to colored and turbid solutions. On
the contrary, electrochemistry has always provided analytical techniques characterized by
instrumental simplicity and moderate cost [22].
Fig. 1. Chemical structure of Quetiapine Fumarate (QTF)
The ion-selective electrodes (ISEs) application in pharmaceutical analysis have increased
due to the advantages of portability, limited sample pretreatment, low energy consumption,
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 53
rapidity, and adaptability to small sample volumes[23,24]. Thus, the development of
membrane sensors offering these advantages for the determination of QTF drug is desirable,
especially given that there are no reported ISEs in the literature used for determination of QTF
drug.
2. EXPERIMANTAL
2.1. Apparatus
A Jenway digital ion analyzer model 3330 (Essex, UK) with Ag/AgCl double junction
reference electrode no. 924017-LO3-Q11C was used for potential measurements. A pH glass
electrode Jenway (Essex, UK) no. 924005-BO3-Q11C was used for pH adjustment.
2.2. Materials
2.2.1. Reference samples
QTF, (99.4%) and its related compounds; DQ and QO (99.8%) were kindly supplied by
National Organization of Drug Control and Research (NODCAR) institute, Cairo, Egypt.
2.2.2. Pharmaceutical formulation
Seroquel® tablets were manufactured by Astra Zeneca, Egypt. Each tablet was labeled to
contain 25 mg of QTF.
2.3. Reagents
All chemicals and reagents used were of analytical grade and water was bi-distilled. Dioctyl
phthalate (DOP) was obtained from Sigma (St. Louis, USA), sodium tetraphenylborate
(NaTPB), tetrahydrofuran (THF) and poly vinyl chloride (PVC) were obtained from BDH
(Poole, England), β-Cyclodextrin (β-CD) [Fluka,Steinheim, Germany]. Potassium chloride and
hydrochloric acid 30-34% were obtained from El-Nasr pharmaceutical chemical company,
Cairo, Egypt.
2.4. Standard solutions
2.4.1. QTF stock standard solution (1×10-2 mol L−1)
The solution was prepared by transferring 0.88 g of pure QTF into a 100-mL volumetric
flask, which was dissolved in sufficient amount of a solvent consisting of 0.1 N HCl: distilled
water in a ratio (1:1), and then the volume was brought up to the mark with the same solvent.
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 54
2.4.2. QTF working standard solutions (1×10-7-1×10-3 mol L-1)
Prepared by suitable dilution from QTF stock standard solution and completed to the
volume with bi-distilled water.
2.4.3. DQ and QO related compounds stock standard solutions (1×10−2 mol L−1)
The solutions were prepared by transferring 0.038 g and 0.039 g of DQ and QO,
respectively into 100-mL volumetric flasks separately and completing the volume with the
same solvent of 0.1 N HCl: bi-distilled water (1:1).
2.5. Procedures
2.5.1. Fabrication of PVC master membrane sensors
For the preparation of sensor I, 0.35 mL of (DOP) as plasticizer was mixed with 0.01 gm
of the cation exchanger (NaTPB) and 0.19 gm PVC in a 5-cm Petri dish. The mixture was
dissolved in 6 mL THF. For sensors II, 0.03 gm of β-CD was added to the previous components.
The Petri dishes were covered with filter paper and left to stand overnight at room temperature
to allow solvent evaporation. Master membranes 0.1 mm in thickness were obtained. From
each master membrane, a disk (about 1.6 cm in diameter) was cut using a cork borer and pasted
using THF to an interchangeable PVC tip that was clipped into the end of an electrode glass
body. The electrodes were then filled with an internal solution of equal volumes of 10−2 mol
L−1 QTF and 10−2 mol L−1 KCl. Ag/AgCl wire (1 mm diameter) was used as an internal
reference electrode. The sensors were conditioned by soaking in 10−2 mol L−1 QTF solution for
24 h, and they were stored in the same solution when not in use. The electrochemical cells for
potential measurements were: Ag/AgCl (internal reference electrode)/ 10−2 mol L−1 QTF
solution, 10−2 mol L−1 KCl (internal reference solution) // PVC membrane// test solution //
Ag/AgCl double junction reference electrode.
2.5.2. Sensors calibration
The conditioned sensors were calibrated by separately transferring 50 mL aliquots of
solutions (1×10−8-1×10−3 mol L−1) of QTF into a series of 100-mL beakers. The membrane
sensors, in conjunction with Ag/AgCl reference electrode, were immersed in the above test
solutions and allowed to equilibrate while stirring. The potential was recorded after stabilizing
to ±1 mV, and the electromotive force (emf) was plotted as a function of the negative logarithm
of QTF molar concentration. The sensors were washed with bi-distilled water after each
measurement.
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 55
2.5.3. Direct potentiometric determination of laboratory prepared mixtures containing
different ratios QTF and its related compounds; DQ and QO
Aliquots of standard DQ and QO solutions (10−3 mol L−1) were prepared using distilled
water and mixed with standard drug solution (10−3 mol L−1) in different ratios. The emf values
of these laboratory-prepared mixtures were recorded and results were compared with the
calibration plot.
2.5.4. Direct potentiometric determination of QTF in Seroquel tablets
A portion of Seroquel tablets powder equivalent to 0.088 gm QTF was transferred
separately into 10-mL volumetric flask and filled to the mark with 0.1 N HCl: bi-distilled water
(1:1) to obtain concentration of 1×10-3 mol L−1. The potentiometric measurement was
performed using the proposed sensors in conjunction with the Ag/AgCl reference electrode,
and the potential reading was compared to the calibration plot.
2.5.5. Determination of QTF in plasma
One millilitre of each of 10−4, 10−5 and 10−6 mol L−1 standard drug solution were added
separately into three 20-mL stoppered shaking tubes each containing 9 mL of plasma and the
tubes were shaken for 1 min. The membrane sensors were immersed in conjunction with the
reference electrode in these solutions and then washed with water between measurements. The
emf produced for each solution was measured by the proposed sensors, and the concentration
of QTF was determined from the corresponding regression equation.
2.5.6. Estimation of the slope, response time and operative life of the proposed sensors
The electrochemical performance of the two proposed sensors was evaluated according to
the IUPAC recommendations [25]. Sensor life span was examined by repeated monitoring of
the slope of the drug calibration curve periodically. The detection limit was taken at the point
of intersection of extrapolated linear segment of drug calibration graph.
The dynamic response time was recorded by increasing QTF concentration by up to 10-
fold. The required time for the sensors to reach values within ±2.0 mV of the final equilibrium
potential was measured.
2.5.7. Effect of pH
The effect of pH on the response of the investigated electrodes was studied using 10−3 and
10−4 mol L−1 solutions of QTF with pH ranging from 2 to 10. The pH was gradually increased
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 56
or decreased by adding aliquots of 0.1 N sodium hydroxide or 0.1 N hydrochloric acid
solutions, respectively. The potential obtained at each pH value (1 pH interval) was recorded.
2.5.8. Sensors selectivity
The potentiometric selectivity coefficients (.
) of the proposed sensors towards
different substances were determined by a separate solution method using the following
equation:
(.
)=
2.303/ +1

Where, (.
) is the potentiometric selectivity coefficient, E1 is the potential measured in
10−3 mol L−1 QTF solution, E2 is the potential measured in 10−3 mol L−1 aqueous interferent
solution, ZA and ZB are the charges of QTF and interfering ion, respectively, αA is the activity
of the drug and 2.303RT/ZAF represents the slope of the investigated sensor
(mV/concentration decade).
3. RESULTS AND DISCUSSION
The development and application of ion-selective electrodes (ISEs) continue to be of
interest for pharmaceutical analysis because these sensors offer the advantages of simple design
and operation, fast response, reasonable selectivity, low detection limit, high accuracy, wide
concentration range, applicability to colored and turbid solutions, and possible interfacing with
automated and computerized systems [26].
Selective membranes in ion selective electrodes have shown both ion exchange and perm
selectivity for the sensor ion [27]. Two selective membrane sensors with and without
incorporation of ionophore were proposed for determination of QTF in its pure substance, drug
product, plasma and in presence of its DQ, QO related compounds (Fig. 2).
(a) (b)
Fig. 2. Chemical structure of Quetiapine N-oxide (QO) (a) and Des-ethanol Quetiapine (DQ)
(b)
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 57
3.1. Sensors fabrication
PVC was used as a matrix in the sensors fabrication being a regular support and
reproducible trap for ion association complexes. PVC requires plasticization and places a
constraint on the choice of mediator [28].Thus in the present work, the optimum available
mediator for fabrication of sensors was found to be DOP and its proportion was optimized to
minimize the electrical asymmetry of the membrane as to keep the sensor as clean as possible
and to stop leaching into the aqueous phase [29]. The fact that QTF acts as a cation, suggests
the use of the cationic ion exchanger such as sodium tetraphenylborate (NaTPB) for the
fabrication of the two sensors.
Cyclodextrins have been applied as sensor ionophores in potentiometric ion selective
electrodes for the determination of several drugs [30-36]. They are known to accommodate a
wide variety of organic, inorganic and biologic guest molecules to form stable host–guest
inclusion complexes or nanostructure supramolecular assemblies in their hydrophobic cavity
while exhibiting high molecular selectivity and enantioselectivity [37]. In the case of natural
CD, cooperative binding with certain guest molecules was mostly attributed to intermolecular
hydrogen bonding between the CD molecules [38].
3.2. Sensors calibration and response time
Based on the IUPAC [25] recommendations the response characteristics of the designed
sensors were assessed. Table 1 displays the results obtained over a period of three months for
the two sensors. Typical calibration plots are shown in Fig. 3. The slope was computed from
the linear part of the calibration graph.
Fig. 3. Profile of the potential in mV versus log concentration of QTF in mol L-1 obtained
with sensors Ι and ΙΙ
The slopes of the calibration plots were 27.5±1.0 and 39.85±1.0 mV/ concentration decades
for sensor I and II, respectively. QTF reacts with TPB to form stable (1:2) water insoluble ion
-150
-100
-50
0
50
100
150
200
0246810
E (mV)
-Log Concentration (mol L-1)
Sensor I
Sensor II
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 58
association complexes, with low solubility product and suitable grain size precipitates. This
ratio was confirmed by the elemental analysis data and by the Nernstian response of the
suggested sensors, which was about 30 mV, the typical value for divalent drugs [25]. The
deviation from the Nernstian slope is due to the fact that the electrodes respond to activities of
the drug rather than the concentration. The sensors displayed constant potential readings within
±2 mV from day to day. The required time for the sensors to reach values within ±1 mV of the
final equilibrium potential after increasing the drug concentration 10-fold was found to be 14
seconds for sensor I and 10 seconds for sensor II.
Table 1. Validation of the response characteristics of the two investigated sensors
Parameter
Sensor Ι
Sensor ΙΙ
Slope (mV/ decade)
a
27.50±0.45
39.85±0.3
Intercept (mV)
53.8±1.55
248.19±1.06
Correlation coefficient (r)
0.9994
0.9996
Linearity range (mol L
-1
)
1×10
-6
-1×10
-2
1×10
-7
- 1×10
-2
Response time (S)
14
10
Working pH range
2.5-7
2.5-7
Stability (weeks)
3
4
LOD (mol L
-1
)
1.8×10
-6
2.0×10
-7
Average Accuracy (% ) ± S.D.
b
98.99±1.12
99.34±0.56
Precision (RSD%,
n=9)
1.5
0.65
2.3
1.34
a Average of five determinations.
b Limit of detection (measured by interception of the extrapolated arms of Fig. 3 )
3.3. Effect of pH
For quantitative measurements with ISEs, studies were carried out to reach the optimum
experimental conditions. The effect of pH on the response of the proposed sensors was studied
to reach the optimum experimental conditions. Figs. 4 and 5 and show the potential-pH profile
of 1×10-3 mol L-1 and 1×10-4 mol L-1 QTF for sensor I and II; respectively. It was apparent that
the sensors responses were fairly constant in solutions of pH values 2.5-7; in this pH range, the
drug is completely ionized, dissociated and sensed. Above pH 7, the potential showed a sharp
decrease that could be due to the formation of non-protonated amino group of QTF. However,
below pH 2.5, the potential displayed by the electrodes were noisy and unbalanced.
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 59
Fig. 4. Effect of pH on the response of suggested sensor Ι [working pH range 2.5-7]
Fig. 5. Effect of pH on the response of suggested sensor ΙΙ [working pH range 2.5-7]
Table 2. Potentiometric selectivity coefficients (.
) of the proposed sensors
Interferent (103 mol L1)
Selectivity coefficient a
Sensor Ι
Sensor ΙΙ
N-oxide
1.9×10-3
2.1×10-3
Des-ethanol
1.5×10-3
1.6×10-3
NaCl
2.5×10-4
1.3×10-4
KCl
5.0×10-5
1.9×10-5
CaCl
2
3.8×10-4
6.3×10-4
MgCO
3
4.4×10-4
1.8×10-4
Sucrose
4.8×10-4
7.9×10-4
Mannitol
5.7×10-4
3.0×10-4
Urea
4.9×10-4
8.3×10-4
a Each value is the average of three determinations
3.4. Sensors selectivity
The effect of interfering substances on the performance of the sensors was studied by the
separate method [26].
The response of the two sensors in the presence of susceptible tablet excipients, organic
and inorganic related substances, was assessed. The calculated selectivity coefficients showed
-140
-120
-100
-80
-60
-40
-20
0
0 5 10 15
E (mV)
pH
10-3 mol L-1
10-4 mol L-1
0
20
40
60
80
100
120
140
0 5 10 15
E (mV)
pH
10-3 mol L-1
10-4 mol L-1
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 60
that the proposed sensors displayed high selectivity, and no significant interference was
observed from the interfering species, (Table 2).
3.5. Potentiometric determination of laboratory prepared mixtures
The results obtained upon analysis of synthetic mixtures containing different ratios of QTF
to the two related compounds; DQ and QO show that sensors Ι and ΙΙ can be successfully used
for selective determination of intact drug in presence of its two related compounds with no
need for prior separation, (Table 3).
Table 3. Determination of QTF in laboratory prepared mixtures containing different ratios of
QTF and its related compounds by the proposed sensors
Ratio of QTF: N-oxide : Des-ethanol
Drug recovery (%) ± S.D.
a
Sensor Ι
Sensor ΙΙ
10:1:1 101.35 ±1.16 100.76±0.64
100:1:1
100.76±0.94
100.32±0.36
1000:1:1
102.24±0.97
101.32±1.01
1:1:1
102.41±1.23
101.59±1.24
1:10:10
101.32±0.94
102.76±1.43
1:100:100
120±1.64
104.42±2.05
1:1000:1000
122±1.86
117.47±2.12
a Average of three determinations
3.6. Potentiometric determination of QTF in plasma
The results obtained for the determination of QTF in spiked human plasma show that a
wide concentration range can be determined by the investigated sensors with high precision
and accuracy. The results presented in Table 4 show no interference from endogenous
substances and that sensor Π is more sensitive so it is preferred to be used in plasma application
as it can measure a concentration lower than QTF drug Cmax (126.9 ng mL-1) [39].
Table 4. Determination of QTF in spiked human plasma by the proposed sensors
Recovery% ± SD
a
Added (mol L
1
)
Sensor Ι
Sensor ΙΙ
10
-5
99.70±0.39
99.65±0.56
10
-6
98.40±0.97
98.37±1.65
10
-7
88.75±1.56
97.85±0.84
a Average of three determinations
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 61
3.7. Potentiometric determination of QTF in Seroquel tablets
The proposed sensors were applied for the analysis of QTF pharmaceutical formulation
(Seroquel tablets). The results prove the applicability of the sensors, as demonstrated by the
accurate and precise percentage recoveries. The susceptible tablet excipients did not show any
interference. Thus, the determination of QTF was carried out without prior treatment or
extraction by using the proposed sensors (Table 5).
Table 5. Determination of QTF in pharmaceutical preparation by the proposed sensors and the
reference HPLC method
Recovery%±SD
a
Item
Sensor Ι
Sensor ΙΙ
Reference method
b
Seroquel ® tablets
labeled to contain 25.0mg QTF
99.67±0.71 99.81±0.82 99.21±0.97
Student’s t-test
c
1.29 (2.44)
0.147(2.201)
-
F-test
c
3.18 (6.338)
2.086(8.845)
-
a Average of three determinations
b HPLC method supplied by Astra Zeneca company through personal communication ;C18 column and mobile
phase; 0.02M dibasic ammonium phosphate: acetonitrile: methanol (39:7:54, v/v/v) and UV detection at 254
nm
c The values in parentheses are the corresponding theoretical values for t and F at P = 0.05
3.8. Statistical comparison of the obtained results with the reference method
To examine the validity of the proposed sensors, the obtained results were compared to
HPLC reference method and no significant difference was observed in accuracy and precision.
The results are shown in Table 5.
4. CONCLUSION
These two membrane sensors are the first in the literature for determination of QTF drug.
The responses of the fabricated sensors are sufficiently precise and accurate, and they
demonstrate the good selectivity and sensitivity of the sensors for the quantitative
determination of QTF in pure form, in laboratory-prepared mixtures with two related
compounds; N-oxide and Des-ethanol Quetiapine, in pharmaceutical formulation and in
plasma. Sensor ΙΙ with the ionophore inclusion is more sensitive and more stable than sensor Ι,
so it is better to be used for plasma application. Moreover, the proposed sensors have the
advantage of eliminating any need for drug pretreatment or separation steps and they are simple
in design, low in cost and they could compete with the many sophisticated methods currently
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 62
available. Thus, the sensors can therefore be used for the routine analysis of QTF in quality-
control laboratories.
REFERENCES
[1] S. M. Cheer, and A. J. Wagstaff, CNS Drugs 18 (2004) 173.
[2] K. Basavaiah, N. Rajendraprasad, P. J. Ramesh, and K. B. Vinay, Thai J. Pharm. Sci. 34
(2010) 146.
[3] B. B. Hiraman, V. Sandip, T. R. Lohiya, and J. M. Umekar, Int. J. Chem. Tech. Res. 1
(2009) 1153.
[4] K. B.Vinay, H. D. Revanasiddappa, P. J. Ramesh, and N. Rajendraprasad, Chem. Ind.
Chem. Eng. Q. 17 (2011) 99.
[5] K. B. Venkata, S. R. Battula, and S. Dubey, J. Chem. 2013 (2013) 1.
[6] M. Gouthami, R. Karthikeyan, and P. S. Babu, Int. Res. J. Pharm. 4 (2013) 189.
[7] K. B. Vinay, H. D. Revanasiddappa, N. Rajendraprasad, P. J. Ramesh, and K. Basavaiah,
JRPS. 2 (2013) 131.
[8] F. Belal, A. Elbrashy, M. Eid, and J. J. Nasr, J. Liq. Chromatogr. Related Technol. 31
(2008) 1283.
[9] S. R. Krishna, B. M. Rao, and N. S. Rao, Rasayan J. Chem. 1 (2008) 466.
[10] P. C. P. Rosa, I. F. R. Pires, B. E. O. Markman, and F. F. Perazzo, JAPS. 3 (2013) 6.
[11] Z. R. Dedania, N. R. Sheth, and R. R. Dedania, IJPSR. 4 (2013) 2406.
[12] B. Dhandapani, A. Somasundaram, S. H. Raseed, M. Raja, and K. Dhanabal, Int. J.
Pharm. Tech. Res. 1 (2009) 139.
[13] S. Hillaert, L. Snoeck, and W. V. d. Bossche, J. Chromatogr. A 1033 (2004) 357.
[14] V. Pucci, R. Mandrioli, A. Ferranti, S. Furlanetto, and M. A. Raggi, J. Pharm. Biomed.
Anal. 32 (2003) 1037.
[15] S. A. Ozkan, B. Dogan, and B. Uslu, Microchim. Acta 153 (2006) 27.
[16] B. Nigovi´c, and J. Spaji´, Talanta 86 (2011) 393.
[17] K. B. Vinay, H. D. Revanasiddappa, and N. Rajendraprasad, Port. Electrochim. Acta 28
(2010) 299.
[18] S. Korrapolu, S. Bollineni, and B. N. Nalluri, J. Chem. Pharm. Res. 4 (2012) 3877.
[19] R. K. Trivedi, and M. C. Patel, Sci. Pharm. 79 (2011) 97.
[20] V. Mittapelli, L. Vadali, S. D. A and M. V. Suryanarayana, Rasayan J. Chem. 3 (2010)
677.
[21] C. Bharathi, K. J. Prabahar, C. S. Prasad, M. S. Rao, G. N. Trinadhachary, V. K. Handa,
R. Dandala, and A. Naidu, Pharmazie 63 (2008) 14.
[22] V. K. Gupta, R. Jain, K. Radhapyari, N. Jadon, and S. Agarwal, Anal. Biochem. 408
(2011) 179.
Anal. Bioanal. Electrochem., Vol.
8
, No.
1
, 2016, 51-63 63
[23] M. Nebsen, G. M. Elsayed, M. Abdelkawy, and S. Z. Elkhateeb, Anal. Bioanal.
Electrochem. 5 (2013) 368.
[24] E. S. Elzanfaly, and M. Nebsen, Anal. Bioanal. Electrochem. 5 (2013) 166.
[25] IUPAC Analytical Chemistry Division, Commission on Analytical Nomenclature, Pure
Appl. Chem. 72 (2000).
[26] T. S. Ma, and S. S. M. Hassan, Organic analysis using ion-selective electrodes, Academic
Press, London (1982).
[27] G. Moody, and J. Thomas, Selective ion sensitive electrodes, chapter 1, Merrow technical
library (1971).
[28] A. M. El-Kosasy, M. Nebsen, M. K. A. El-Rahman, M. Y. Salem, and M. G. El-Bardicy,
Talanta 85 (2011) 913.
[29] H. M. A. Shawish, A. M. Khedr, K. I. Abed-Almonem, and M. Gaber, Talanta 101 (2012)
211.
[30] N. K. Ramadan, and H. A. Merey, Acta Chim. Slov. 59 (2012) 870.
[31] H. E. Zaazaa, S. S. Abbas, H. A. M. Essam, and M. G. El-Bardicy, Port. Electrochim.
Acta 30 (2012) 335.
[32] A. M. El-Kosasy, O. A. El-Aziz, N. Ebrahim, and L. A. Fattah, Anal. Bioanal.
Electrochem. 4 (2012) 357.
[33] M. R. Elghobashy, and M. R. Rezk, Anal. Bioanal. Electrochem. 6 (2014) 461.
[34] E. S. Elzanfaly, H. E. Zaazaa, and H. A. Merey, Acta Chim. Slov. 60 (2013) 256.
[35] M. Nebsen, N. K. Ramadan, and E. S. Elzanfaly, Res. Rev. Electrochem. 2 (2010) 33.
[36] M. Nebsen, M. K. A. El-Rahman, A. M. El-Kosasy, M. Y. Salem, and M. G. El-Bardicy,
Port. Electrochim. Acta 29 (2011) 165.
[37] B. Kieser, C. Fietzek, R.Schmidt, G. Belge, U.Weimar, V.Schurig, and G. Gauglitz,
Anal.Chem.74 (2002) 3005.
[38] E. E. Sideris, G. N. Valsami, M. A. Koupparis, and P. E. Macheras, Eur. J. Pharm. Sci. 7
(1999) 271.
[39] E. A. Junior, L. F. Duarte, and E. M. Suenaga, J. Bioequiv. Availab. 3 (2011) 178.
Copyright © 201
6
by CEE (Center of Excellence in Electrochemistry)
ANALYTICAL & BIOANALYTICAL ELECTROCHEMISTRY (http://www.abechem.com)
Reproduction is permitted for noncommercial purposes.
... Moreover, the research field of electronic sensors is quickly developing through the ongoing application of cutting-edge technologies [8,9]. Nevertheless, only a few works on the electrochemical determination of QF have been proposed in the literature so far, using bare or modified (with molecular imprinted polymers, graphene, and selective films) glassy carbon and carbon paste electrodes [10][11][12][13][14][15][16][17][18]. All these electrochemical methods of QF determination involve the use of separate "large-size" external reference and counter electrodes; therefore, they do not have any degree of miniaturization and integration. ...
... Sensors 2021, 21, x FOR PEER REVIEW 2 of 10 trodes [10][11][12][13][14][15][16][17][18]. All these electrochemical methods of QF determination involve the use of separate "large-size" external reference and counter electrodes; therefore, they do not have any degree of miniaturization and integration. ...
... To enhance the electrochemical performance of the 3D-printed integrated sensor in the voltammetric determination of QF, the composition of the supporting electrolyte, the effect of the accumulation time and potential, and the scanning waveform were optimized in a solution containing 50 × 10 −7 mol × L −1 QF. QF is a weak base with 3.3 and 6.8 pKa, and in solutions with acidic pH values the piperazine moiety is protonated, increasing the adsorption of positively charged molecules of QF on the electrode surface [12][13][14][15][16]. It has been shown before that, at neutral and alkaline pH values, the peak heights of QF are reduced and may be split into two peaks [12][13][14][15][16]. ...
Article
Full-text available
In this work, we developed a novel all-3D-printed device for the simple determination of quetiapine fumarate (QF) via voltammetric mode. The device was printed through a one-step process by a dual-extruder 3D printer and it features three thermoplastic electrodes (printed from a carbon black-loaded polylactic acid (PLA)) and an electrode holder printed from a non-conductive PLA filament. The integrated 3D-printed device can be printed on-field and it qualifies as a ready-to-use sensor, since it does not require any post-treatment (i.e., modification or activation) before use. The electrochemical parameters, which affect the performance of the sensor in QF determination, were optimized and, under the selected conditions, the quantification of QF was carried out in the concentration range of 5 × 10⁻⁷–80 × 10⁻⁷ mol × L⁻¹. The limit of detection was 2 × 10⁻⁹ mol × L⁻¹, which is lower than that of existing electrochemical QF sensors. The within-device and between-device reproducibility was 4.3% and 6.2% (at 50 × 10⁻⁷ mol × L⁻¹ QF level), respectively, demonstrating the satisfactory operational and fabrication reproducibility of the device. Finally, the device was successfully applied for the determination of QF in pharmaceutical tablets and in human urine, justifying its suitability for routine and on-site analysis.
... Because QF (pKa 3.3, 6.8) is considered a weak base, it is positively charged in low pH conditions due to the protonated piperazine moiety, increasing the interaction of the molecules on the modified-electrode surface. 10,11,21,22 So, the peak current was decreased with increment of pH ( Figure 4A). As a result, the optimal pH (pH = 6) was chosen for other electrochemical and analytical studies. ...
... Finally, the analytical performance of the engineered chemosensor was compared with the previously developed sensors for the quantification of QF (Table 1). Table 1 10,11,22,[24][25][26][27][28][29] illustrates the differences between the engineered electrochemical sensor and previously described methods for QF detection. ...
Article
Quetiapine fumarate (QF) is an antipsychotic drug that has been most widely prescribed as an antipsychotic. In this regard, sensitive recognition of QF in bodily fluids must be done accurately. In this work, an electrochemical sensor for QF detection was fabricated, using GNSs‐PDA@SiO2 modified rGO stabilized on glassy carbon electrode (GCE). According to the electrical nature of gold nanoparticles (GNPs), polydopamine (PDA), and its composition with nano‐silica, the proposed hybrid material is able to enhance the electro‐oxidation signals of QF towards its sensitive detection in complex biological media. The morphology of synthesized polymeric nanocomposites and various surfaces of electrodes were investigated using Field Emission Scanning Electron Microscopy (FESEM) and Energy‐Dispersive X‐Ray Spectroscopy (EDS) methods. Using the square wave voltammetry technique, the fabricated electrochemical sensor could detect QF in the linear range of 500 μM to 3 mM, which low limit of quantification (LLOQ) was obtained as 500 μM, indicating the sensor's appropriate sensitivity. For the first time, the application of novel hybrid material (GNSs‐PDA@SiO2) for pharmaceutical analysis in human plasma was studied using electrochemical sensor technology. Based on the obtained analytical results, engineered nano‐surface led to entrapment and oxidation of QF in real samples. So, a novel and efficient method for the analysis of QF was designed and validated, which opens a new horizon for pharmaceutical analysis and Therapeutic Drug Monitoring (TDM).
... QUET was quantitatively determined officially through United States Pharmacopeia (USP) [17]. It is also found in literature either individually or in the presence of related metabolites, co-administered drugs, or potential impurities using the following analytical techniques: High Performance Liquid Chromatography (HPLC) [18][19][20][21][22][23], Liquid Chromatography with tandem mass spectrometry (LC-MS/MS) [24], Gas Chromatography with tandem mass spectrometry (GC-MS/MS) [25], Thin Layer Chromatography (TLC) [20,26,27], spectrophotometry [28,29], fluorescence [30,31], capillary zone electrophoresis (CZE) [28,32], and electrochemical methods [33][34][35]. ...
Article
Full-text available
A sustainable HPTLC-densitometric method was developed for quantitative determination of Quetiapine (QUET), Levodopa (LD) and Carbidopa (CD) in presence of Dopamine (DOP) as an internal standard. This applicable technique was achieved by spiking human plasma and extraction was performed using the protein precipitation approach. The mobile phase used was acetone, dichloromethane, n-butanol, glacial acetic acid and water (3: 2.5: 2: 2: 1.75, by volume). Method validation was done according to US-FDA guidelines and was able to quantify Quetiapine, Levodopa and Carbidopa in the ranges of 100–4000, 200–8000 and 30–1300 ng/mL, respectively. Bioanalytical method validation parameters were assessed for the studied drugs. Finally, the analytical suggested methodology was evaluated using various green and white analytical chemistry metrics and other tools, such as the green solvent selection tool, analytical eco-scale, green analytical procedure index, analytical greenness metric approach and the red–green–blue algorithm tool. The results revealed that the applied analytical method had a minor impact on the environment and is a relatively greener option than other previously reported chromatographic methods. Graphical Abstract
... This method has various advantages, such as being simple, sensitive, inexpensive, low detection limit and environment friendly. Different electrochemical methods reported (125)(126)(127)(128)(129)(130)(131)(132)(133)(134)(135) for quantification of QTF include voltammetry, potentiometry, polarography and their analytical parameters, which are discussed in Table V. ...
Article
Full-text available
Atypical antipsychotics are newer second-generation antipsychotics with weak dopamine type 2 blocking but potent 5-HT2 antagonistic activity. They are considered first-line treatments for schizophrenia and gradually replace typical antipsychotics. Extrapyramidal side effects are minimal, and they tend to improve impaired cognitive function in psychotics. Quetiapine fumarate is an atypical antipsychotic drug used to treat schizophrenia, mania and depression in people with bipolar disorder combined with other drugs or alone. Quetiapine was developed in 1985 and approved for medical use in the USA in 1997. Thorough computer-aided literature, surveys revealed that numerous analytical methods were reported over the years. The present study reviews analytical methods with their validation parameters published during the last 22 years (1999–2021) either as a single entity or combination in dosage form, and determination from biological samples. Novel strategies for increasing separation quality, such as QbD analysis and green spectroscopy, were discovered during the evaluation, and this review can be utilized for further research reference.
... Wishart, et al,2018). Several approaches have been reported for the quantitative determination of QU in bulk, and pharmaceutical and biological samples which include spectrophotometric (Bagade , 2009;Vessalli, 2013;Lakshmi, 2009), electrochemical [Nigovic´, 2011;Nebsen, 2016), HPLC (Semin, 2015 ;Kumar, 2013;Venkata, 2013;Youssef, 2016) and HPTLC (Sathiyaa, 2010). Aripiprazole (AR),7-(4-[4-(2,3-dichlorophenyl)-1 piperazinyl] (butoxy)-3,4-dihydro-2(1H)-quinolinone is a novel, atypical antipsychotic drug for treatment of schizophrenia (D. ...
Article
In this research, the advantages of molecularly imprinted polymer (MIP) materials have been used to develop a new electrochemical sensor for determination of quetiapine (QTP) drug. MIP nanoparticles were synthesized by precipitation polymerization method and used as QTP recognition elements in the composition of modified carbon paste electrode (CPE) for selective and sensitive assay of this drug. Cyclic voltammetry (CV) and square wave voltammetry (SWV) techniques were used for electrochemical analysis. Some parameters affecting the sensor performance were optimized and under optimal conditions, the proposed sensor showed linear responses with QTP concentration in the range of 1.6 × 10-8 to 2.5 × 10-6 M (R2 = 0.9964). The limits of detection (LOD) and quantification (LOQ) were calculated 5.04 × 10-9 M and 1.68 × 10-8 M respectively. Also, the amounts of %RSD for evaluation of repeatability and reproducibility of the proposed sensors were respectively obtained 2.19 and 3.02%. The method was successfully applied to determination of QTP in its pharmaceutical formulation and human urine samples.
Article
Full-text available
Fabrication of organic PVC membrane based coated wire electrode for sensitive, fast, precise and simple determination of quetiapine in pharmaceutical formulation and urine samples is demonstrated. The new electrode was constructing using quetiapine: tetraphenyl borate ion pair complex as electro-active material, PVC as supporting matrix, 2-nitrophenyl octyl ether as mediator of solvent and potassium tetrakis (4-chlorophenyl) borate as lipophilic additive. The electrode provides Nernstian response (57 ± 0.2 mV/decade) over a wide concentration range of 1×10⁻⁵ to 1×10⁻² mol L⁻¹ of quetiapine with lower limit of detection (3.2×10⁻⁶ mol L⁻¹), fast response time (less than ten seconds) and relatively long life span (30 days). Stability with verification of the suitability of the electrode to be applied in the analysis of drug quality control in pharmaceutical and biological (urine) samples was assessed. The results obtained revealed a good agreement with those obtained from independent standard method (high performance liquid chromatography). In the pharmaceutical analysis application, the recovery of the quetiapine selective electrode ranging from 98.83 to 103.27 %, the confidence of the two methods is 95% and the standard deviation is 2.49. While in the biological analysis of urine, the recovery of the electrode with respect to the standard method ranging from 96.45 to 97.48 %, the confidence is 95 % and the standard deviation is 1.48.
Article
Full-text available
In the process for the preparation of quetiapine fumarate (1), six unknown impurities and one known impurity (intermediate) were identified ranging from 0.05-0.15% by reverse-phase HPLC. These impurities were isolated from crude samples using reverse-phase preparative HPLC. Based on the spectral data, the impurities were characterized as 2-[4-dibenzo[b,f][1,4]thiazepine-11-yl-1 -piperazinyl]1 -2-ethanol (impurity I, desethanol quetiapine), 11-[(N-formyl)-1-piperazinyl]-dibenzo[b,f][1,4]thiazepine (impurity II, N-formyl piperazinyl thiazepine), 2-(2-hydroxy ethoxy)ethyl-2-[2-[4-dibenzo[b,f][1,4]thiazepine-11- piperazinyl-1-carboxylate (impurity III, quetiapine carboxylate), 11-[4-ethyl-1-piperazinyl]dibenzo [b,f][1,4] thiazepine (impurity IV, ethylpiperazinyl thiazepine), 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]1-ethyl ethanol [impurity V, ethyl quetiapine), 1,4-bis[dibenzo[b,f][1,4]thiazepine-11-yl] piperazine [impurity VI, bis(dibenzo)piperazine]. The known impurity was an intermediate, 11-piperazinyldibenzo [b,f][1,4]thiazepine (piperazinyl thiazepine). The structures were established unambiguously by independent synthesis and co-injection in HPLC to confirm the retention times. To the best of our knowledge, these impurities have not been reported before. Structural elucidation of all impurities by spectral data (1H NMR, 13C NMR, MS and IR), synthesis and formation of these impurities are discussed in detail.
Article
Quetiapine (Seroquel®), a dibenzothiazepine derivative, is an atypical antipsychotic with demonstrated efficacy in acute schizophrenia. In short-term, randomised, double-blind trials, it was usually more effective than placebo, and was generally effective against both positive and negative symptoms. Overall, quetiapine (up to 750 mg/day) was at least as effective as chlorpromazine (up to 750 mg/day) and had similar efficacy to haloperidol (up to 16 mg/day) in patients with acute schizophrenia in randomised, double-blind trials; it was at least as effective as haloperidol 20 mg/day in patients with schizophrenia unresponsive or partially responsive to previous antipsychotic treatment. Improvements in overall psychopathology and positive and negative symptoms with quetiapine (up to 800 mg/day) were similar to those with risperidone (up to 8 mg/ day) or olanzapine (15 mg/day) [interim analysis]. Efficacy was maintained for at least 52 weeks in open-label follow-up studies in adult and elderly patients. Quetiapine improved cognitive function versus haloperidol, and depressive symptoms and hostility/aggression versus placebo. Quetiapine is well tolerated. It is associated with placebo-level incidence of extrapyramidal symptoms (EPS) across its entire dose range, appears to have a low risk for EPS in vulnerable patient groups (e.g. the elderly, adolescents or patients with organic brain disorders) and has a more favourable EPS profile than risperidone. Irrespective of dose, quetiapine, unlike risperidone and amisulpride, does not elevate plasma prolactin levels compared with placebo, and previously elevated levels may even normalise. Quetiapine appears to have minimal short-term effects on bodyweight and a favourable long-term bodyweight profile. Preliminary studies indicate that there is a high level of patient acceptability and satisfaction with quetiapine. In conclusion, quetiapine has shown efficacy against both positive and negative symptoms of schizophrenia, and has benefits in improving cognitive deficits, affective symptoms and aggression/hostility. The beneficial effects of quetiapine have been maintained for at least 52 weeks. Quetiapine was effective and well tolerated in hard-to-treat patients, and may be of particular use in these individuals. It is at least as effective as standard antipsychotics and appears to have similar efficacy to risperidone and olanzapine. The relative risk/benefit profile of quetiapine compared with other atypical antipsychotics requires further research in head-to-head trials, although quetiapine’s relatively benign tolerability profile distinguishes it from other commonly used atypical agents, particularly with respect to bodyweight, EPS and plasma prolactin levels. Overall, quetiapine has an excellent risk/benefit profile and is a suitable first-line option for the treatment of schizophrenia. Overview of Pharmacodynamic Properties Quetiapine is a dibenzothiazepine derivative, with a relatively higher binding affinity for serotonin 5-HT2 receptors (drug concentration required for 50% inhibition of radioligand binding [IC50] 148 nmol/L) than for dopamine D2 receptors (IC50 329 nmol/L). The drug’s negligible affinity for muscarinic receptors suggests a low risk for anticholinergic adverse effects. In animal models, quetiapine has shown clozapine-like antipsychotic activity predictive of efficacy against both positive and negative symptoms, a low liability to induce extrapyramidal symptoms (EPS) and a reduced propensity to affect prolactin levels. Furthermore, in vitro studies of limbic selectivity suggest that the pharmacological effects of quetiapine are selective for the mesolimbic and mesocortical dopamine systems (responsible for antipsychotic effects), but not the nigrostriatal dopamine system (responsible for EPS). Overview of Pharmacokinetic Properties Oral quetiapine (75–250mg every 8 hours) is rapidly absorbed and demonstrates dose-proportional increases in maximum steady-state plasma concentrations and areas under the plasma concentration-time curves from 0 to 8 hours at steady state. Absorption is not significantly affected by food. Quetiapine has a large apparent volume of distribution and is approximately 83% plasma protein bound. Quetiapine is extensively metabolised in the liver; the major metabolic pathway is sulphoxidation by cytochrome P450 (CYP) 3A4. The drug is excreted primarily in the urine (≈73%) as inactive metabolites. The elimination half-life of quetiapine is approximately 6 hours. The pharmacokinetics of quetiapine do not differ in men compared with women, or in adolescents compared with adults and appear unaffected by cigarette smoking or ethnic background. In contrast, apparent oral clearance was up to 50% lower in elderly (aged 63–85 years) than in younger patients (aged 18–43 years). Patients with hepatic cirrhosis or severe renal impairment (creatinine clearance 8–33 mL/min/1.73m2) had reduced (by ≈25%) mean oral clearance compared with healthv controls. Quetiapine may potentially interact with drugs that are potent inducers (e.g. phenytoin, carbamazepine, barbiturates, rifampicin or glucocorticoids) or inhibitors (e.g. ketoconazole, itraconazole, fluconazole and erythromycin) of CYP3A4. Therapeutic Efficacy In short-term, randomised, double-blind trials in patients with acute schizophrenia, quetiapine (up to 750 mg/day) was generally significantly more effective than placebo at improving psychopathology (Brief Psychiatric Rating Scale [BPRS] total score, p ≤ 0.05; Clinical Global Impression [CGI] scales, p ≤ 0.01). The drug has shown efficacy against both positive (improvement in BPRS positive symptoms cluster score, p = 0.003 for quetiapine ≤750 mg/day) and negative (measured using Scale for the Assessment of Negative Symptoms, p ≤ 0.05) symptoms of schizophrenia versus placebo. Responses observed with quetiapine were clinically meaningful (defined as an improvement of ≥30% from baseline in BPRS total score) in approximately 50% of recipients. Overall, quetiapine (up to 750 mg/day) was at least as effective as chlorpromazine (mean 384 mg/day) and had similar efficacy to haloperidol (up to 16 mg/day) in the management of patients with acute schizophrenia in randomised, double-blind trials of 6–12 weeks’ duration (measured using BPRS and Positive and Negative Symptom Scale [PANSS] total scores, and response rates). The similar efficacy of quetiapine to haloperidol in this patient group was confirmed in a meta-analysis of four double-blind trials. Furthermore, quetiapine 600 mg/day was at least as effective as haloperidol 20 mg/day in the treatment of patients with schizophrenia nonresponsive or partially responsive to previous antipsychotic treatment (fluphenazine titrated to 20 mg/day for 4 weeks); indeed, clinical response (improvement of ≥20% in PANSS score) was higher in quetiapine than in haloperidol recipients (52.2% vs 38.0%, p = 0.043). In addition, quetiapine (up to 750 mg/day) was effective in the management of schizophrenia in patients who were switched from standard (e.g. haloperidol) or atypical antipsychotic agents (including olanzapine and risperidone) following an inadequate response or intolerance in a noncomparative trial; most patients switched to quetiapine had a decrease of ≥1 point on the Index of Clinical Benefit, and significant improvements from baseline were observed at week 12 in PANSS and CGI Severity of Illness scores (both p < 0.001). Interim results suggest similar efficacy for quetiapine (600 mg/day), olanzapine (15 mg/day) and risperidone (5 mg/day) in a small, randomised, rater-blinded trial. Furthermore, improvements in overall psychopathology and the positive and negative symptoms of schizophrenia were similar with quetiapine (up to 800 mg/ day) to those with risperidone (up to 8 mg/day) in a double-blind trial in patients with acute schizophrenia, as were response rates (26.5% and 26.9%) in this trial, or in a nonblind trial in patients with psychoses. In this latter trial, there were no significant differences between treatments in a subgroup of patients with schizophrenia. In a preliminary analysis, quetiapine improved symptoms and overall psychopathology in a small number of patients with first-episode schizophrenia. Improvements with quetiapine were maintained for up to 130 weeks in adult patients with schizophrenia and for at least 52 weeks in elderly patients with the disease in open-label, follow-up studies. In randomised, double-blind trials in patients with schizophrenia, quetiapine also had benefits in improving cognitive function (especially verbal reasoning and fluency) compared with haloperidol (p < 0.05) and depressive symptoms compared with placebo or risperidone. Posthoc analyses suggest that quetiapine (150–750 mg/day) is effective compared with placebo in the treatment of patients displaying hostility and aggression (p < 0.001 for reduction in Behavioural Agitation Scores). Tolerability Quetiapine is well tolerated in patients with schizophrenia. Dizziness, orthostatic hypotension, dry mouth and dyspepsia were the only adverse events with an incidence of ≥5% that occurred in at least twice as many quetiapine as placebo recipients in a pooled analysis of 3- to 6-week placebo-controlled trials. Most adverse events were mild to moderate in intensity. There was no significant difference between quetiapine and placebo groups in overall incidence of treatment discontinuation due to adverse events. The tolerability of quetiapine in long-term trials was similar to that in short-term trials. Quetiapine has a low propensity to induce EPS in patients with schizophrenia in both short- and long-term treatment. Importantly, placebo-level EPS occurred across all quetiapine dosages tested (75–750 mg/day) in a fixed-dose study. EPS occurred with a significantly lower incidence in quetiapine than in haloperidol or chlorpromazine recipients with schizophrenia, and quetiapine had a more favourable EPS profile than risperidone in patients with DSM-IV psychoses; quetiapine recipients were less likely to experience substantial EPS or receive concurrent medication for EPS than risperidone recipients (both p < 0.001). Current data suggest that quetiapine has a low risk for EPS in vulnerable patient groups, including the elderly, adolescents and patients with organic brain disorders; however, additional research is needed to confirm these predominantly preliminary results. Unlike risperidone and amisulpride, quetiapine (across its therapeutic dose range) does not appear to be associated with sustained increases in plasma prolactin levels; indeed, reductions in prolactin levels were noted in many patients in the quetiapine clinical trials programme. Furthermore, quetiapine may normalise prolactin levels in patients previously treated with antipsychotics. The placebo-level effect of quetiapine on plasma prolactin levels is reflected in the low incidence of hormonal and sexual adverse events in the quetiapine clinical trials programme. Quetiapine appears to have a minimal short-term effect on bodyweight and a favourable effect on bodyweight in the long term. There was little change in corrected QT intervals and no clinically significant changes in clinical chemistry parameters with quetiapine therapy in clinical trials. In addition, agranulocytosis or lens changes have not been causally linked to quetiapine treatment. Long-term treatment with quetiapine was associated with good patient acceptability and satisfaction in an open-label multicentre study using a nonvalidated questionnaire. Pharmacoeconomic Considerations Limited pharmacoeconomic analyses suggest that, despite its relatively high acquisition cost, quetiapine may not add to the overall costs of treating schizophrenia and has the potential to be cost saving, although additional research is required. Results from a Markov model (constructed, in part, from a randomised, double-blind trial in patients nonresponsive or partially responsive to previous antipsychotic therapy) indicate that, over 5 years, the higher acquisition cost of quetiapine relative to haloperidol was offset by lower costs for other medications, inpatient hospitalisations and outpatient care; thus, the two treatments had similar overall per-patient costs (£38 106 vs £38 350; year of costing not reported). Indirect costs were not considered in this analysis, which was from the perspective of the UK National Health Service. Quetiapine was the dominant treatment relative to risperidone, achieving greater effectiveness for less cost in a cost-utility analysis of clinical data from a 4-month, randomised, open-label study in outpatients with schizophrenia or other psychotic disorders. Average daily costs for quetiapine and risperidone were SUS6.38 and $US7.85; incremental gains in utilities (0.23 vs 0.12; last-observation-carried-forward analyses) equated to an average incremental gain in quality-adjusted life years for quetiapine recipients of 3.85 years per patient (p < 0.05). Dosage and Administration In adult patients with schizophrenia, quetiapine is licensed to dosages of 750 or 800 mg/day. The target dosage of quetiapine recommended in the manufacturer’s prescribing information is 300–400 or 450 mg/day, although the manufacturer more recently suggests that the initial target dosage should be 600 mg/day to achieve optimum response. A faster rate of titration (increments of 200 mg/day) than that recommended in the current prescribing information (25–50mg twice daily) may be appropriate in acutely ill patients. Patients responding to quetiapine should receive the lowest effective dosage for maintenance therapy. A slower rate of titration and lower target dose should be considered in elderly patients and those with a predisposition to hypotensive reactions. An initial dosage of 25 mg/day is recommended in patients with hepatic impairment, with subsequent increments of 25–50 mg/day until an effective dosage is reached.
Article
This paper reports the construction and evaluation of two ion selective electrodes for the determination midodrine hydrochloride (MD) by direct potentiometry in pure drug substance and in tablet formulations. Precipitation based technique was used for fabrication of the first membrane sensor (sensor 1) using phosphotungestate (PT) and dioctylphthalate (DOP) as cation exchanger and solvent mediator, respectively. beta-cyclodextrin (beta-CD)-based technique with PT as a fixed anionic site in PVC matrix was used for fabrication of the second membrane sensor (sensor 2). The proposed sensors showed fast, stable Nernstian responses of 54 and 56 mV/decade for sensors 1 and 2, respectively, across a relatively wide MD concentration range (1x 10(-4) to 1 x 10(-1) mol/L and 5 x 10(-5) to 1 x 10(-1) mol/L for sensor 1 and 2, respectively) in the pH range of 5-7. Sensor I and sensor 2 can be used for three and two weeks, respectively without any measurable change in sensitivity. The suggested electrodes succeeded to determine intact MD in the presence of up to 10% of its degradation product and displayed good selectivity in presence of common inorganic and organic species.
Article
The electrooxidative behaviour and determination of quetiapine (QTP), a dibenzothiazepine derivative and antipsychotic agent, on a glassy carbon disc electrode was investigated using cyclic (CV), linear sweep (LSV), differential pulse (DPV) and Osteryoung square wave voltammetry (OSWV). Fully validated DP and SW voltammetric procedures are described for the determination of QTP. QTP in pH 3.5 acetate buffer solution presents a well-defined anodic response, studied by the proposed methods. This main response was due to the irreversible, diffusion-controlled, one-electron and one-proton oxidation of the aliphatic nitrogen of the piperazine ring. Under optimal conditions, a detection limit of 4.0 × 10−8 mol L−1 for DPV and 1.33 × 10−7 mol L−1 for OSWV, and a linear calibration graph in the range from 4.0 × 10−6 to 2.0 × 10−4 mol L−1 were obtained for both methods. The procedure was successfully applied to the determination of the drug in tablets, human serum and human urine with good recoveries. The detection limits were 6.20 × 10−7 mol L−1 and 5.92 × 10−7 mol L−1 in human serum and 1.44 × 10−7 mol L−1 and 1.31 × 10−6 mol L−1 in human urine, for the DPV and OSWV method, respectively.
Article
The interaction of diflunisal ion (DF) with beta-cyclodextrin (betaCD), gamma-cyclodextrin (gammaCD), and hydroxypropyl-beta-cyclodextrin (HPbetaCD) was studied in phosphate buffer, pH 7.4, at 5-37 degrees C and various CD concentrations using a home-made diflunisal ion-selective electrode. Typical direct binding plots and Scatchard plots were obtained with HPbetaCD. The Scatchard model for one class of binding sites was used for the estimation of binding parameters for the DF/HPbetaCD interaction. The estimates for n (number of binding sites per CD molecule) were in all cases very close to unity, indicating 1:1 complexation. The association constant (K) estimates decrease with increasing temperature. Sigmoidal direct binding plots and concave-downwards Scatchard plots were obtained with various betaCD or gammaCD concentrations. The Hill model was used for the estimation of the binding parameters for the DF/betaCD and DF/gammaCD interactions. Both the Hill coefficients and the binding constants were markedly dependent on the CD concentration. These findings indicate the cooperative character of DF/betaCD and DF/gammaCD interactions. The free energy change, DeltaG, and the thermodynamic parameters, DeltaH and DeltaS, were estimated for each of the interactions studied using the Van't Hoff equation.
Article
A capillary zone electrophoretic method has been developed and optimized for separation of four atypical antipsychotics (AAPs): clothiapine (cT), clozapine (cZ), olanzapine (O), and quetiapine (Q). A three-level full-factorial design was applied to study the effect of the pH and molarity of the running buffer on separation. Combination of the studied parameters permitted the separation of the four AAPs, which was best carried out using 80 mM sodium phosphate buffer (pH 3.5). The same system can also be applied for the quantitative determination of these compounds. The method was then validated regarding linearity, precision, and accuracy. Especially, the possibility of simultaneous quantification and identification of the active ingredient in the finished product is very attractive.
  • K Basavaiah
  • N Rajendraprasad
  • P J Ramesh
  • K B Vinay
K. Basavaiah, N. Rajendraprasad, P. J. Ramesh, and K. B. Vinay, Thai J. Pharm. Sci. 34 (2010) 146.
  • B B Hiraman
  • V Sandip
  • T R Lohiya
  • J M Umekar
B. B. Hiraman, V. Sandip, T. R. Lohiya, and J. M. Umekar, Int. J. Chem. Tech. Res. 1 (2009) 1153.
  • K B Vinay
  • H D Revanasiddappa
  • P J Ramesh
  • N Rajendraprasad
K. B.Vinay, H. D. Revanasiddappa, P. J. Ramesh, and N. Rajendraprasad, Chem. Ind. Chem. Eng. Q. 17 (2011) 99.